by Precedence Research a new report on asthma and COPD drugs market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for predicting the market’s future. The global asthma and COPD drugs market size was valued at US$ 35.31 billion in 2021. The global asthma and COPD drugs market is projected to reach US$ 56.7 billion by 2030, registering a compound annual growth rate (CAGR) of 5.4% during the forecast period from 2022 to 2030.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1711
Global asthma and COPD drugs market report offers various segments analysis by size, trends, growth factors, opportunities, and key country outlook to 2030. The report offers a detailed analysis and information as per asthma and COPD drugs, and market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.
Asthma and COPD Drugs Market Report Scope
| Report Coverage | Details |
| Market Size by 2030 | USD 56.7 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 5.4% |
| Largest Market | North America |
| Fastest Growing Market | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Diseases, Medication Class, Distribution Channel, Geography |
The company profiling of leading market players is included this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.
Read Also@ Anticoagulants Market is Anticipated to Grow US$ 70 Bn By 2030
Some of the prominent players in the asthma and COPD drugs market include:
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co. Inc
- Grifols S.A.
- Novartis AG
- Cipla Inc.
- Abbott
- Astellas Pharma
- Hoffmann-La Roche Ltd
- Glenmark Pharmaceuticals
Asthma and COPD Drugs Market Segmentation
By Diseases
- Asthma
- COPD
By Medication Class
- Combination Drugs
- Bronchodilators
- Inhaled Corticosteroids (ICS)
- Short Acting Beta Agonists (SABA)
- Long Acting Beta Agonists (LABA)
- Leukotriene Antagonists (LTA)
- Anticholinergics
- Anti-Inflammatories
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Key Questions are
- What are the key factors influencing the asthma and COPD drugs market in each region?
- How much value will the global market generate by the end of the forecast period?
- What will be the CAGR of the global market between 2022 and 2030?
- What would be the Y-o-Y growth trend of the global market between 2022 and 2030?
- What is the future scope and current trends in technologies of the global market?
- What is the revenue of the global market based on segments?
- Which key strategies are used by top players of the global market?
- Which are the leading companies in the global market?
- What are the essential strategies by key stakeholders in the market to expand their geographic presence?
- What are the major advancements witnessed in the global market?
Research Objectives and Research Approach
The comprehensive report on the global asthma and COPD drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global asthma and COPD drugs market.
It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global asthma and COPD drugs market in terms of type, application, region and others. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global market.
Why should you invest in this report?
If you are aiming to enter the global asthma and COPD drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for asthma and COPD drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market
5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma and COPD Drugs Market, By Diseases
8.1. Asthma and COPD Drugs Market, by Diseases Type, 2022-2030
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. COPD
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class
9.1. Asthma and COPD Drugs Market, by Medication Class, 2022-2030
9.1.1. Combination Drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bronchodilators
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhaled Corticosteroids (ICS)
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Short Acting Beta Agonists (SABA)
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Long Acting Beta Agonists (LABA)
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Leukotriene Antagonists (LTA)
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Anticholinergics
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel
10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2022-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Drug Stores
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Teva Pharmaceutical Industries Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Grifols S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Cipla Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Glenmark Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1711
Our Press Release@ https://www.precedenceresearch.com/press-releases
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
